Search

Your search keyword '"Klaassen Z"' showing total 22 results
Start Over Author "Klaassen Z" Publisher elsevier b.v.
22 results on '"Klaassen Z"'

1. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic[Formula presented]

Author

Wallis C. J. D., Novara G., Marandino L., Bex A., Kamat A. M., Karnes R. J., Morgan T. M., Mottet N., Gillessen S., Bossi A., Roupret M., Powles T., Necchi A., Catto J. W. F., Klaassen Z., Wallis, C. J. D., Novara, G., Marandino, L., Bex, A., Kamat, A. M., Karnes, R. J., Morgan, T. M., Mottet, N., Gillessen, S., Bossi, A., Roupret, M., Powles, T., Necchi, A., Catto, J. W. F., and Klaassen, Z.

Subjects
Prostate cancer, Coronavirus disease 2019, Sstemic therapy, SARS-CoV-2, Bladder cancer, Pneumonia, Viral, Delayed treatment, COVID-19, Disease Management, Kidney cancer, Penile cancer, Combined Modality Therapy, Time-to-Treatment, Coronavirus, Betacoronavirus, Testicular cancer, Upper tract urothelial carcinoma, Risk Factors, Humans, Surgery, Triage, Coronavirus Infections, Pandemics, Urogenital Neoplasms
Abstract

The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to patients, treating health care professionals, and the health care system.

Published
2020

18. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.

Author

Magee, D.E., Hird, A.E., Klaassen, Z., Sridhar, S.S., Nam, R.K., Wallis, C.J.D., and Kulkarni, G.S.

Subjects
*ADVERSE health care events, *CANCER chemotherapy, *IMMUNOTHERAPY, *META-analysis, *TUMORS
Abstract

Immunotherapy agents are an innovative oncological treatment modality and as a result their use has expanded widely. Understanding the treatment-related adverse events (AEs) of these drugs compared with traditional chemotherapy is crucial for clinical practice. A systematic review of studies indexed in Medline (PubMed), Embase, Web of Science, and the Cochrane Databases from January 2000 to 14 February 2019 was conducted. Randomized clinical trials comparing immunotherapy [cytotoxic T-lymphocyte protein-4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1)] with standard-of-care chemotherapy in the treatment of advanced solid-organ neoplasms were included if AEs were reported as an outcome. Primary outcome was AEs ≥ grade 3 in severity. Secondary outcomes were proportion of overall AEs, treatment discontinuation due to AEs, deaths due to AEs, and specific AEs [fatigue, diarrhea, acute kidney injury (AKI), colitis, pneumonitis, and hypothyroidism]. Paule–Mandel pooling and a random effects model were used to produce odds ratios (ORs) for measures of effects. Among 10 598 abstracts screened, we included 22 studies involving 12 727 patients. In the immunotherapy group, 16.5% of patients developed an AE ≥ grade 3 in severity, compared with 41.09% in the chemotherapy arm [OR = 0.26, 95% confidence interval (CI) 0.19–0.35, I 2 = 92%]. Patients receiving immunotherapy also had lower odds of developing an AE overall (OR = 0.35, 95% CI 0.28–0.44; I 2 = 77%), terminating therapy due to an AE (OR = 0.55, 95% CI 0.39–0.78, I 2 = 80%), or dying from a treatment-related AE (OR = 0.67, 95% CI 0.46–0.98, I 2 = 0%). When treated with chemotherapy versus immunotherapy, patients more frequently experienced fatigue (25.10% versus 15.83%), diarrhea (14.97% versus 11.13%), and AKI (1.79% versus 1.31%). However, colitis (1.02% versus 0.26%), pneumonitis (3.36% versus 0.36%), and hypothyroidism (6.82% versus 0.37%) were more common in those treated with immunotherapy. Treatment of advanced solid-organ malignancies with immunotherapy compared with traditional chemotherapy is associated with a lower risk of AEs. • 22 trials involving 12,727 patients with advanced solid organ malignancies were included in this meta-analysis. • Patients receiving immunotherapy were less likely to develop severe adverse events than those receiving chemotherapy. • Fewer terminations due to adverse events or deaths due to adverse events occurred in the immunotherapy group. • Fatigue and diarrhea were more likely to occur in patients treated with chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. 683P Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database

Author

Freedland, S.J., Howard, L., Wallis, C.J.D., De Hoedt, A., Aronson, W.J., Polascik, T.J., Amling, C.J., Kane, C.J., Cooperberg, M.R., Terris, M.K., Wu, Y., and Klaassen, Z.

Subjects
*CASTRATION-resistant prostate cancer, *RADICAL prostatectomy, *ANDROGEN deprivation therapy, *METASTASIS
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results